{"id":6102,"date":"2026-08-24T09:10:00","date_gmt":"2026-08-24T16:10:00","guid":{"rendered":"https:\/\/www.iths.org\/participate\/?p=6102"},"modified":"2026-08-24T09:10:00","modified_gmt":"2026-08-24T16:10:00","slug":"a-study-of-brenipatide-in-participants-with-opioid-use-disorder-renew-op-1","status":"publish","type":"post","link":"https:\/\/www.iths.org\/participate\/a-study-of-brenipatide-in-participants-with-opioid-use-disorder-renew-op-1\/","title":{"rendered":"A Study of Brenipatide in Participants With Opioid Use Disorder (RENEW-Op-1)"},"content":{"rendered":"
<\/div>\n

The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. <\/p>\n

See more at https:\/\/clinicaltrials.gov\/study\/NCT07420283?titles=Brenipatide&rank=3<\/a><\/p>\n

Participant Eligibility<\/h3>\n

– Between the ages of 18-75
\n– Currently taking sublingual buprenorphine
\n– Able to participate once a week for at least 68 weeks<\/p>\n

Contact<\/h3>\n

Olivia Gregorich
\n(206) 657-7492<\/p>\n

<\/p>\n

Additional Study Details<\/h3>\n

Full Study Title<\/strong>
\nA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study with a Separate Open-label Cohort to Evaluate the Efficacy and Safety of Brenipatide as Adjunctive Treatment to Transmucosal Buprenorphine with or without Naloxone in Early Recovery of Participants with Opioid Use Disorder (RENEW-Op-1)
\n<\/span><\/p>\n

Study ID:<\/strong> J2S-MC-GZMG<\/div>\n
ClinicalTrials.gov Link:<\/strong> NCT07420283<\/a><\/div>\n
<\/div>\n
Start Date:<\/strong> 02\/13\/2026<\/div>\n
End Date:<\/strong> 03\/01\/2028<\/div>\n
<\/div>\n

Investigator(s)<\/strong>
\nElenore Bhatraju
\n<\/span>
\nAccepts Healthy Volunteers?<\/strong>
\nNo<\/span><\/p>\n

Study Site(s)<\/strong> <\/p>\n

\n

Harborview Medical Center<\/h4>\n

325 9th Ave
\nSeattle, Washington 98104<\/p><\/div>\n

\n

<\/h4>\n<\/p><\/div>\n
<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. See more at https:\/\/clinicaltrials.gov\/study\/NCT07420283?titles=Brenipatide&rank=3 Participant Eligibility – Between the ages of 18-75 –…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[17],"tags":[1722,1723],"class_list":["post-6102","post","type-post","status-publish","format-standard","hentry","category-mental-health-and-behavior","tag-buprenorphine","tag-opioid-use-disorder"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/comments?post=6102"}],"version-history":[{"count":2,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6102\/revisions"}],"predecessor-version":[{"id":6104,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6102\/revisions\/6104"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/media?parent=6102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/categories?post=6102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/tags?post=6102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}